Cibus, Inc. Class A (CBUS)

Cibus, Inc.'s stock price has been impacted by earnings reports, public offerings, board appointments, and business developments in the past six months. Earnings reports included the 3Q25 Financial Results Conference Call, the announcement of financial results for the fourth quarter ended December 31, 2025, and the upcoming First Quarter 2026 Financial Results. Public offerings in January and March 2026 aimed to strengthen the balance sheet and support trait development. Craig Wichner and Thomas Urban were appointed to the Board of Directors. Business developments included positive field trial results for HT2 edited canola, the first customer payment from its Sustainable Ingredients program, and the transfer of gene-edited herbicide tolerance materials in rice to its partner Interoc. Cibus was upgraded to a Zacks Rank #2 (Buy), and analysts have adjusted price targets. The stock has experienced high volatility, and shareholders have been substantially diluted. Cibus's stock was trading at $1.74 at the start of the year and has since decreased by 17.2% to $1.44 as of May 9, 2026.

The agricultural industry, in which Cibus, Inc. operates, is highly seasonal, causing Cibus's sales and operating results to fluctuate significantly. The sale of plant and seed products is dependent on growing and harvesting seasons, which vary annually and across different geographies. Weather and environmental conditions can also impact the quality, volume, and cost of seed produced, as well as demand and product mix. Historically, February has shown the highest probability of positive returns for CBUS, while May may not be an ideal month to invest.

Cibus, Inc. is an agricultural technology company specializing in precision gene editing for agricultural applications, utilizing its Rapid Trait Development System (RTDS) to develop improved crop traits without foreign DNA. The company focuses on enhanced disease resistance, herbicide tolerance, and yield optimization, offering trait development services and licensing partnerships. Cibus's major products include gene-edited traits for key row crops such as canola, pennycress, potato, rice, soybean, corn, and wheat.

Headquartered in San Diego, California, Cibus, Inc. serves customers and partners across North America and Europe, maintaining research and development facilities. Through strategic alliances, Cibus has expanded its global footprint, offering tailored solutions to support sustainable agriculture and meet evolving market needs. The company is targeting commercial launches in its USA and LATAM geographic markets for its Rice program in 2027 and 2028, respectively.

Cibus, Inc.'s reputation has seen positive developments, particularly in the regulatory and partnership spheres. The company was selected by the UK Government as a technology partner in its Farming Innovation Programme. The European Union reached a political agreement on New Genomic Techniques legislation in December 2025, advancing the regulatory framework for gene-edited plants. These events suggest a growing recognition and acceptance of Cibus's gene-editing technologies within the agricultural industry and by governmental bodies.

The ownership structure of Cibus, Inc. is a mix of institutional, retail, and individual investors. Insiders hold approximately 26.45% to 31.16% of the stock, with Rory Riggs being the largest individual shareholder. Institutional investors hold between 0.50% and 33.81% of the company's stock. Retail investors hold a significant portion, approximately 43% to 62.93% of the company.